Pfizer Embraces Biotech-Like Speed To Advance BCMA Bispecific
Phase II Pivotal Trial Under Way For Elranatamab In Multiple Myeloma
Executive Summary
Chris Boshoff, Pfizer Oncology chief development officer, said lessons from the rapid pace of the company’s COVID-19 vaccine program are being applied to elranatamab and other cancer therapies.
You may also be interested in...
Pfizer Returns Bavencio Rights To Merck KGaA, Closing An IO Era
The arrangement ends a nearly 10-year collaboration between Pfizer and Merk KGaA on the PD-L1 inhibitor that, despite some success, never reached its ultimate goal.
Pfizer Pays $43bn For Seagen With Goal Of Rapidly, Globally Advancing ADCs
Pfizer expects its acquisition of Seagen to result in $10bn in new revenue by 2030 as the big pharma applies its resources to the target company’s pioneering antibody-drug conjugate technology.
Multiple Myeloma Bispecifics Vie For Leadership Based On Safety, Combinability
Updates at ASH for bispecifics targeting BCMA, GPRC5D and FcRH5 from Regeneron, Janssen, Pfizer, Roche, AbbVie and Harpoon show monotherapy efficacy, initial combination data and potential safety differentiation.